TY - JOUR
T1 - NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery
AU - Chetvertkov, Mikhail
AU - Monroe, James Ira
AU - Boparai, Jaskaran
AU - Solberg, Timothy D.
AU - Pafundi, Deanna H.
AU - Ruo, Russell L.
AU - Gladstone, David J.
AU - Yin, Fang Fang
AU - Chetty, Indrin J.
AU - Benedict, Stanley
AU - Followill, David S.
AU - Xiao, Ying
AU - Sohn, Jason W.
N1 - Funding Information:
This project was supported by grants U24CA180803 (IROC) and U10CA180868 (NRG Oncology Operations) from the National Cancer Institute (NCI).
Funding Information:
Conflict of Interest: DF reports grants from NCI, during the conduct of the study. IC reports grants from Varian Medical Systems and Philips HealthCare, outside the submitted work.
PY - 2020/11/27
Y1 - 2020/11/27
N2 - Purpose: To assess stereotactic radiotherapy (SRT)/stereotactic body radiotherapy (SBRT) practices by polling clinics participating in multi-institutional clinical trials. Methods: The NRG Oncology Medical Physics Subcommittee distributed a survey consisting of 23 questions, which covered general technologies, policies, and procedures used in the Radiation Oncology field for the delivery of SRT/SBRT (9 questions), and site-specific questions for brain SRT, lung SBRT, and prostate SBRT (14 questions). Surveys were distributed to 1,996 radiotherapy institutions included on the membership rosters of the five National Clinical Trials Network (NCTN) groups. Patient setup, motion management, target localization, prescriptions, and treatment delivery technique data were reported back by 568 institutions (28%). Results: 97.5% of respondents treat lung SBRT patients, 77.0% perform brain SRT, and 29.1% deliver prostate SBRT. 48.8% of clinics require a physicist present for every fraction of SBRT, 18.5% require a physicist present for the initial SBRT fraction only, and 14.9% require a physicist present for the entire first fraction, including set-up approval for all subsequent fractions. 55.3% require physician approval for all fractions, and 86.7% do not reposition without x-ray imaging. For brain SRT, most institutions (83.9%) use a planning target volume (PTV) margin of 2 mm or less. Lung SBRT PTV margins of 3 mm or more are used in 80.6% of clinics. Volumetric modulated arc therapy (VMAT) is the dominant delivery method in 62.8% of SRT treatments, 70.9% of lung SBRT, and 68.3% of prostate SBRT. Conclusion: This report characterizes SRT/SBRT practices in radiotherapy clinics participating in clinical trials. Data made available here allows the radiotherapy community to compare their practice with that of other clinics, determine what is achievable, and assess areas for improvement.
AB - Purpose: To assess stereotactic radiotherapy (SRT)/stereotactic body radiotherapy (SBRT) practices by polling clinics participating in multi-institutional clinical trials. Methods: The NRG Oncology Medical Physics Subcommittee distributed a survey consisting of 23 questions, which covered general technologies, policies, and procedures used in the Radiation Oncology field for the delivery of SRT/SBRT (9 questions), and site-specific questions for brain SRT, lung SBRT, and prostate SBRT (14 questions). Surveys were distributed to 1,996 radiotherapy institutions included on the membership rosters of the five National Clinical Trials Network (NCTN) groups. Patient setup, motion management, target localization, prescriptions, and treatment delivery technique data were reported back by 568 institutions (28%). Results: 97.5% of respondents treat lung SBRT patients, 77.0% perform brain SRT, and 29.1% deliver prostate SBRT. 48.8% of clinics require a physicist present for every fraction of SBRT, 18.5% require a physicist present for the initial SBRT fraction only, and 14.9% require a physicist present for the entire first fraction, including set-up approval for all subsequent fractions. 55.3% require physician approval for all fractions, and 86.7% do not reposition without x-ray imaging. For brain SRT, most institutions (83.9%) use a planning target volume (PTV) margin of 2 mm or less. Lung SBRT PTV margins of 3 mm or more are used in 80.6% of clinics. Volumetric modulated arc therapy (VMAT) is the dominant delivery method in 62.8% of SRT treatments, 70.9% of lung SBRT, and 68.3% of prostate SBRT. Conclusion: This report characterizes SRT/SBRT practices in radiotherapy clinics participating in clinical trials. Data made available here allows the radiotherapy community to compare their practice with that of other clinics, determine what is achievable, and assess areas for improvement.
KW - best practices
KW - clinical trials
KW - radiotherapy
KW - stereotactic body radiotherapy
KW - stereotactic radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85097577274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097577274&partnerID=8YFLogxK
U2 - 10.3389/fonc.2020.602607
DO - 10.3389/fonc.2020.602607
M3 - Article
AN - SCOPUS:85097577274
VL - 10
JO - Frontiers in Oncology
JF - Frontiers in Oncology
SN - 2234-943X
M1 - 602607
ER -